Berberine interacts with gut microbiota and its potential therapy for polycystic ovary syndrome

Clin Exp Pharmacol Physiol. 2023 Aug 21. doi: 10.1111/1440-1681.13814. Online ahead of print.ABSTRACTBerberine (BBR) is an isoquinoline alkaloid extracted from Chinese medicinal plants showing a tight correlation with gut microbiota. Polycystic ovary syndrome (PCOS) is a prevalent reproductive and endocrine disorder syndrome among women of childbearing age. Dysbiosis, the imbalance of intestinal microorganisms, is a potential factor that takes part in the pathogenesis of PCOS. Recent evidence indicates that berberine offers promise for treating PCOS. Here, we review the recent research on the interaction between berberine and intestinal microorganisms, including the changes in the structure of gut bacteria, the intestinal metabolites after BBR treatment, and the effect of gut microbiota on the bioavailability of BBR. We also discuss the therapeutic effect of BBR on PCOS in terms of gut microbiota and its potential mechanisms.PMID:37604463 | DOI:10.1111/1440-1681.13814
Source: Clinical and Experimental Pharmacology and Physiology - Category: Drugs & Pharmacology Authors: Source Type: research